Acute ST-elevation Myocardial Infarction and Interleukin-6 Inhibition Cardioprotection and Novel Therapeutic Strategies

AK Anstensrud - 2023 - duo.uio.no
Despite urgent myocardial reperfusion with percutaneous coronary intervention (PCI),
morbidity and mortality remain substantial in patients presenting with acute myocardial …

Interleukin-6 Receptor Inhibition in Acute St-Segment Elevation Myocardial Infarction: A Randomised Placebo-Controlled Trial

K Broch, AK Anstensrud, S Woxholt, K Sharma… - 2021 - papers.ssrn.com
Background: Prompt myocardial revascularisation with percutaneous coronary intervention
(PCI) reduces infarct size and improves outcomes in patients with acute ST segment …

The role of IL-6 receptor trans-signalling in ischemia-reperfusion injury, infarct healing and future adverse events in patients with ST-Elevation Myocardial Infarction

I Tollefsen, C Shetelig, P Hoffmann… - European Heart …, 2021 - academic.oup.com
Background Inflammation has emerged as a new treatment target in patients with coronary
artery disease, and inflammation seems to play an important role in the ischemia/reperfusion …

Randomized trial of interleukin-6 receptor inhibition in patients with acute ST-segment elevation myocardial infarction

K Broch, AK Anstensrud, S Woxholt, K Sharma… - Journal of the American …, 2021 - jacc.org
Background Prompt myocardial revascularization with percutaneous coronary intervention
(PCI) reduces infarct size and improves outcomes in patients with ST-segment elevation …

High levels of interleukin-6 are associated with final infarct size and adverse clinical events in patients with STEMI

IM Tøllefsen, C Shetelig, I Seljeflot, J Eritsland… - Open …, 2021 - openheart.bmj.com
Objective Inflammation has emerged as a new treatment target in patients with coronary
artery disease and inflammation seems to play an important role in ischaemia/reperfusion …

Interleukin-6 plasma levels are elevated in patients with acute myocardial infarction and predict death or recurrent infarction within 1 year-a case-control study

MA Matter, YJ Wang, VA Rossi, D Heg… - European Heart …, 2023 - academic.oup.com
Background Acute myocardial infarction (AMI) harbours marked inflammatory components.
While cytokines of the same family have been causally related to patient outcome, the role of …

Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation …

AK Anstensrud, S Woxholt, K Sharma, K Broch… - Open …, 2019 - openheart.bmj.com
Introduction Interleukin-6 (IL-6) may be involved in ischaemia-reperfusion injury and
myocardial remodelling after myocardial infarction (MI). We have recently shown that IL-6 …

Ischemic Time and Interleukin 6 Levels in Acute Myocardial Infarction

HE Groot, IV van Blokland, JC Karper, P van der Harst… - Circulation, 2021 - Am Heart Assoc
Introduction: Increased levels of the inflammatory cytokine interleukin 6 (IL-6) after
percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) are …

Early inhibition of IL-6 signalling after an acute MI improves myocardial salvage

I Fernandez-Ruiz - Nature Reviews Cardiology, 2021 - nature.com
A new randomized clinical trial shows that tocilizumab, a monoclonal antibody that inhibits IL-
6 signalling by binding to the IL-6 receptor, increases myocardial salvage in patients with …

227 Infarct size in a rat model of acute myocardial infarction is reduced by interleukin-6 trans-signalling blockade using sgp130fc but not an anti-il-6r monoclonal …

MJ George, D Stuckey, V Taylor, A Hingorani, D Gilroy - Heart, 2017 - heart.bmj.com
Introduction Interleukin-6 (IL-6) is elevated during acute myocardial infarction (AMI)
particularly after reperfusion with primary percutaneous coronary intervention (PPCI). Higher …